Orchestra BioMed surpasses enrollment target in BACKBEAT pivotal trial of AVIM hypertension therapy

• Orchestra BioMed surpassed full enrollment in the BACKBEAT pivotal trial of its AVIM Therapy for uncontrolled hypertension in pacemaker patients.
• 330 patients were randomized as of Sept. 30, 2026, exceeding the planned enrollment level intended to support the primary analysis.
• Primary endpoint results have not been presented; data are slated for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027.
• Positive results could support Medtronic marketing application submissions to the FDA and other regulators for the therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010800PRIMZONEFULLFEED9837338) on October 01, 2026, and is solely responsible for the information contained therein.